

Financial Tear Sheet

Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the high-value drug profiling and therapeutic tissues markets

 [2017 Annual Report](#)  [Investor Presentation](#)

Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.71
Change (%)	▼ 0.03 (1.72%)
Volume	838,231
52 Week Low	\$0.91
Market Cap	\$189,529,514
Rolling EPS	-0.36
PE Ratio	0
Shares Outstanding	110,835,973
Data as of 05/18/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations &
 Corporate
 Communications
Phone: 858-224-1092
Email:
 skunszabo@organovo.com

Recent Press Releases & Upcoming Events

05/14/18

Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results

05/10/18

Organovo to Present New Preclinical Data for Its Liver Therapeutic Tissue IND-Track Programs at the World Advanced Therapies and Regenerative Medicine Congress

05/03/18

Organovo and Samsara Sciences Partner with New Manufacturing USA Institute

Date	Title
05/31/18 5:00 p.m. ET	Organovo Holdings, Inc. Fourth Quarter Earnings Conference Call

SEC Filings

Filing Date	Form
05/17/18	4
05/17/18	4
05/17/18	4
05/17/18	4

Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Senior Vice President, Human Resources
Paul Gallant	General Manager